摘要:
A drug effect-adverse effect prediction system includes a clinical data analysis table generating part, for each combination of genotypes relating to a drug effect or adverse effect, for generation of an analysis table for handling cases related to presence or absence of the drug effect or adverse effect. The system also includes a reliability analysis part, a discrimination formula generating part, a prediction part, and a discrimination formula optimizing part.
摘要:
A method for determining the risk of adverse effects of irinotecan (CPT-11), a synthetic anticancer drug, by detecting polymorphisms in the TATA box within the promoter region of the UDP-glucuronosyl transferase gene. A kit for detecting the adverse effects of irinotecan containing at least one pair of nucleic acid probes.
摘要:
A method for determining the risk of adverse effects of irinotecan (CPT-11), a synthetic anticancer drug, by detecting polymorphisms in the TATA box within the promoter region of the UDP-glucuronosyl transferase gene. A kit for detecting the adverse effects of irinotecan containing at least one pair of nucleic acid probes.
摘要:
The present invention relates to a scoring system for the prediction of cancer recurrence by selecting genes and/or proteins whose expression patterns associated with recurrence of cancer, and generating formulae with the selected genes and/or proteins for the prediction of cancer recurrence. The present invention relates to a kit for determining the likelihood of recurrence of cancer, comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction to examine the expression of at least 2, 4, 6, 10, 12 or more genes and/or proteins, that are indicative of cancer recurrence.
摘要:
The present invention relates to a method of defining the differentiation grade of tumor by selecting genes and/or proteins whose expression level correlates with each differentiation grade of tumor, measuring the expression of the genes and/or proteins of human tumor tissues in each differentiation grade. The present invention also relates to the use of these genes and/or proteins for diagnosing the differentiation grade of tumor and for screening anti-cancer agents for tumor treatment.
摘要:
To provide an effective factor extraction system in which samples are generated artificially from a sample group and a virtual sample set is created so that even when the number of sample is relatively small, specific factors can be selected/extracted with high reliability by using the virtual sample set. The effective factor extraction system comprises a section (3) for extracting samples arbitrarily from sample sets (X(15), Y(16)) and creating a plurality of paired virtual sample sets (X(17), Y(18)), a statistical quantity operating section (5) for reading out the feature value held by sample contained in respective virtual sample sets and operating the average value and the variance, a section (6) for operating Fisher ratio from the average value (21) and the variance (22), and a section (8) for testing significant factors using the operated Fisher ratio.
摘要:
To provide an effective factor extraction system in which samples are generated artificially from a sample group and a virtual sample set is created so that even when the number of sample is relatively small, specific factors can be selected/extracted with high reliability by using the virtual sample set. The effective factor extraction system comprises a section for extracting samples arbitrarily from sample sets and creating a plurality of paired virtual sample sets, a statistical quantity operating section for reading out the feature value held by sample contained in respective virtual sample sets and operating the average value and the variance, a section for operating Fisher ratio from the average value and the variance, and a section for testing significant factors using the operated Fisher ratio.
摘要:
The present invention relates to a scoring system for the prediction of cancer recurrence by selecting genes and/or proteins whose expression patterns associated with recurrence of cancer, and generating formulae with the selected genes and/or proteins for the prediction of cancer recurrence. The present invention relates to a kit for determining the likelihood of recurrence of cancer, comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction to examine the expression of at least 2, 4, 6, 10, 12 or more genes and/or proteins, that are indicative of cancer recurrence.
摘要:
The present invention provides a novel method for detection of liver cancer. This method detects high-sensitively, high-specifically, simply and accurately liver cancer, especially that in early stage by identifying and/or quantifying methylation on particular genes and/or their DNA fragments in clinical specimens, and by combining said methylated DNA values with existing tumor marker values and/or DNA amounts in blood. This invention also detects a precancerous lesion, detects a risk of recurrence after treatment of liver cancer, detects malignancy of liver cancer and monitors progression of liver cancer with time by the same method. As for particular genes, BASP1 gene, SPINT2 gene, APC gene, CCND2 gene, CFTR gene, RASSF1 gene and SRD5A2 gene are mentioned.
摘要:
The present invention provides a novel method for detection of liver cancer. This method detects high-sensitively, high-specifically, simply and accurately liver cancer, especially that in early stage by identifying and/or quantifying methylation on particular genes and/or their DNA fragments in clinical specimens, and by combining said methylated DNA values with existing tumor marker values and/or DNA amounts in blood. This invention also detects a precancerous lesion, detects a risk of recurrence after treatment of liver cancer, detects malignancy of liver cancer and monitors progression of liver cancer with time by the same method. As for particular genes, BASP1 gene, SPINT2 gene, APC gene, CCND2 gene, CFTR gene, RASSF1 gene and SRD5A2 gene are mentioned.